{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T18:47:13Z","timestamp":1786214833361,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO10201500002C"],"award-info":[{"award-number":["HHSO10201500002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO10201600031C"],"award-info":[{"award-number":["HHSO10201600031C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO10201700012C"],"award-info":[{"award-number":["HHSO10201700012C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Office of the Assistant Secretary of Preparedness and Response"},{"name":"US Department of Defense, Defense Threat Reduction Agency","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The effect of malaria infection on the immunogenicity of the recombinant vesicular stomatitis virus\u2013Zaire Ebola virus envelope glycoprotein (GP) vaccine (rVSV\u0394G-ZEBOV-GP) (ERVEBO) is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) vaccinated 7998 asymptomatic adults with rVSV\u0394G-ZEBOV-GP during the 2014\u20132016 Ebola epidemic. In STRIVE\u2019s immunogenicity substudy, participants provided blood samples at baseline and at 1, 6, and 9\u201312 months. Anti-GP binding and neutralizing antibodies were measured using validated assays. Baseline samples were tested for malaria parasites by polymerase chain reaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 506 participants enrolled in the immunogenicity substudy and had \u22651 postvaccination antibody titer. Of 499 participants with a result, baseline malaria parasitemia was detected in 73 (14.6%). All GP enzyme-linked immunosorbent assay (ELISA) and plaque reduction neutralization test (PRNT) geometric mean titers (GMTs) at 1, 6, and 9\u201312 months were above baseline, and 94.1% of participants showed seroresponse by GP-ELISA (\u22652-fold rise and \u2265200 ELISA units\/mL), while 81.5% showed seroresponse by PRNT (\u22654-fold rise) at \u22651 postvaccination assessment. In participants with baseline malaria parasitemia, the PRNT seroresponse proportion was lower, while PRNT GMTs and GP-ELISA seroresponse and GMTs showed a trend toward lower responses at 6 and 9\u201312 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Asymptomatic adults with or without malaria parasitemia had robust immune responses to rVSV\u0394G-ZEBOV-GP, persisting for 9\u201312 months. Responses in those with malaria parasitemia were somewhat lower.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab243","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T11:06:22Z","timestamp":1621163182000},"page":"1907-1915","source":"Crossref","is-referenced-by-count":19,"title":["Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus\u2013Zaire Ebola Virus Envelope Glycoprotein"],"prefix":"10.1093","volume":"224","author":[{"given":"Barbara E","family":"Mahon","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Simon","sequence":"additional","affiliation":[{"name":"Global Clinical Development\u2013Vaccines, Merck & Co, Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Alain","family":"Widdowson","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Samai","sequence":"additional","affiliation":[{"name":"College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rogier","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Legardy-Williams","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Liu","sequence":"additional","affiliation":[{"name":"Biostatistics, Merck & Co, Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lange","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolynn","family":"DeByle","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pinner","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schuchat","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Slutsker","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"2021120504472281500_CIT0001","volume-title":"Ebola strategy\u2014Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation","author":"World Health Organization.","year":"2014"},{"key":"2021120504472281500_CIT0002","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"2021120504472281500_CIT0003","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus\u2013Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"2021120504472281500_CIT0004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2021120504472281500_CIT0005","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021120504472281500_CIT0006","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"2021120504472281500_CIT0007","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"2021120504472281500_CIT0008","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone Trial to Introduce a Vaccine against Ebola: an evaluation of rVSV\u2206G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"2021120504472281500_CIT0009","author":"World Health Organization."},{"key":"2021120504472281500_CIT0010","volume-title":"ERVEBO\u00ae (Ebola Zaire vaccine, live) now registered in four African countries, within 90 days of reference country approval and WHO prequalification. Democratic Republic of the Congo one of the first African countries to register ERVEBO","author":"Eisele","year":"2020"},{"key":"2021120504472281500_CIT0011","volume-title":"Ervebo: Ebola Zaire vaccine (rVSV\u2206G-ZEBOV-GP, live)","author":"European Medicine Agency.","year":"2019"},{"key":"2021120504472281500_CIT0012","volume-title":"WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries","author":"Jasarevic","year":"2019"},{"key":"2021120504472281500_CIT0013","volume-title":"ERVEBO, Ebola Zaire vaccine, live","author":"US Food and Drug Administration.","year":"2020"},{"key":"2021120504472281500_CIT0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smim.2018.07.003","article-title":"Correlates of vaccine-induced protective immunity against Ebola virus disease","volume":"39","author":"Medaglini","year":"2018","journal-title":"Semin Immunol"},{"key":"2021120504472281500_CIT0015","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"Lancet Microbe"},{"key":"2021120504472281500_CIT0016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"2021120504472281500_CIT0017","doi-asserted-by":"crossref","first-page":"e5547","DOI":"10.1371\/journal.pone.0005547","article-title":"Mucosal immunization of cynomolgus macaques with the VSVDeltaG\/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses","volume":"4","author":"Qiu","year":"2009","journal-title":"PLoS One"},{"key":"2021120504472281500_CIT0018","doi-asserted-by":"crossref","first-page":"e1002402","DOI":"10.1371\/journal.pmed.1002402","article-title":"Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: a phase I randomised trial","volume":"14","author":"Agnandji","year":"2017","journal-title":"PLoS Med"},{"key":"2021120504472281500_CIT0019","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"2021120504472281500_CIT0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021120504472281500_CIT0021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14760584.2018.1546582","article-title":"Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?","volume":"17","author":"Huttner","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2021120504472281500_CIT0022","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"Immunogenicity, lot consistency, and extended safety of rVSV\u0394G-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J Infect Dis"},{"key":"2021120504472281500_CIT0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1017\/S0031182015001249","article-title":"Immunity to malaria in an era of declining malaria transmission","volume":"143","author":"Fowkes","year":"2016","journal-title":"Parasitology"},{"key":"2021120504472281500_CIT0024","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1017\/S0031182015000761","article-title":"Immune activation and induction of memory: lessons learned from controlled human malaria infection with plasmodium falciparum","volume":"143","author":"Scholzen","year":"2016","journal-title":"Parasitology"},{"key":"2021120504472281500_CIT0025","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(78)92403-0","article-title":"Impairment of the immune response to vaccination after acute malaria","volume":"1","author":"Williamson","year":"1978","journal-title":"Lancet"},{"key":"2021120504472281500_CIT0026","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2021120504472281500_CIT0027","volume-title":"World Health Organization World malaria report 2018","year":"2018"},{"key":"2021120504472281500_CIT0028","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4269\/ajtmh.20-1055","article-title":"Effects of gamma-irradiated human serum samples from rVSV\u0394G-ZEBOV-GP (V920) vaccines using a validated plaque-reduction neutralization test","volume":"104","author":"Grant-Klein","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2021120504472281500_CIT0029","doi-asserted-by":"crossref","first-page":"e56677","DOI":"10.1371\/journal.pone.0056677","article-title":"Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR","volume":"8","author":"Lucchi","year":"2013","journal-title":"PLoS One"},{"key":"2021120504472281500_CIT0030","first-page":"263","article-title":"Detection and identification of the four malaria parasite species infecting humans by PCR amplification","volume":"50","author":"Snounou","year":"1996","journal-title":"Methods Mol Biol"},{"key":"2021120504472281500_CIT0031","doi-asserted-by":"crossref","first-page":"e0215457","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the filovirus animal nonclinical group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS One"},{"key":"2021120504472281500_CIT0032","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus\u2014Zaire Ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"key":"2021120504472281500_CIT0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2020.04.066","article-title":"Humoral and cellular immune response induced by rVSVDeltaG-ZEBOV-GP vaccine among frontline workers during the 2013\u20132016 West Africa Ebola outbreak in Guinea","author":"Boum","year":"2020","journal-title":"Vaccine"},{"key":"2021120504472281500_CIT0034","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-019-1200-9","article-title":"Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017","volume":"570","author":"Dwyer-Lindgren","year":"2019","journal-title":"Nature"},{"key":"2021120504472281500_CIT0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4269\/ajtmh.19-0076","article-title":"Effect of gamma irradiation on the antibody response measured in human serum from subjects vaccinated with recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine","volume":"101","author":"Grant-Klein","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2021120504472281500_CIT0036","author":"World Health Organization."},{"key":"2021120504472281500_CIT0037","author":"World Health Organization."},{"key":"2021120504472281500_CIT0038","volume-title":"Ebola vaccinations launch in guinea","author":"Hackett","year":"2021"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab243\/38837022\/jiab243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/11\/1907\/41429429\/jiab243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/11\/1907\/41429429\/jiab243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T04:48:28Z","timestamp":1638679708000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/11\/1907\/6278485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,5,20]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab243","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,5,20]]}}}